Announcement PDF RNS Number : 4226X OptiBiotix Health PLC 18 February 2025 OptiBiotix Health plc ("OptiBiotix"or the"Company") Launch of Daily Nouri FeelFull product in America SlimBiome®containing finished products OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces the launch of FeelFull, containing SlimBiome®, by Daily Nouri ("Nouri") in the United States of America (USA). Daily Nouri is a well-known brand in the USA known for its science-backed, clinically supported probiotic and prebiotic solutions which impact on gut health.Nouri sell their products in their online store (www.dailynouri.com),on Amazon, and in stores of some of the largest retailers in the USA such as Walmart and Albertsons. FeelFull is a prebiotic lemonade drink containing SlimBiome® formulated by Nouri which has been created "to helpconsumers regulate appetite, curb cravings, and support metabolic health by increasing viscosity in the stomach, slowing gastric emptying, and stabilising blood sugar levels to create a feeling of fullness and help satiate overall desire for food intake.".The lemonade is a powdered drink in portable stick packs which can be mixed with water with 'on pack' health claims which state daily use supports 'reduced appetite and cravings' and a 'feeling of fullness' derived from OptiBiotix's multiple clinical studies. 'On pack' health claims are important in differentiating products in the weight management market and are an area of high consumer interest since the launch of the appetite reducing anti-obesity drugs. Nouri forecast a requirement for ten metric tons of SlimBiome®in year one. Stephen O'Hara, CEO of OptiBiotix, commented: "Nouriis a well-known and respected brand in the USA with an online presence and products in major retailers like Walmart and Albertsons, the second largest supermarket in the USA. This initial launch is for a FeelFull lemonade product with the potential for further products within the FeelFull range depending on sales progress. This launch represents a step forward for the Company's products in the USA market and the first of a number of launches planned with partners across the USA. "With recent product launches in India (Morepen, Amazon), China, large parts of Asia (Philippines, Vietnam, Indonesia, Malysia and Thailand) and now the USA, the Company is growing its brand presence in international markets around the world. This global approach, whilst taking longer than a single market approach but with greater upside, has the potential to create multiple revenue streams and build a substantial global business in the years ahead." This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. For further information, please contact: OptiBiotix Health plc Neil Davidson, Chairman Stephen O'Hara, Chief Executive www.optibiotix.com Contact via Walbrook below Cairn Financial Advisers LLP (NOMAD) Liam Murray / Ludovico Lazzaretti Tel: 020 7213 0880 Peterhouse Capital Limited (Broker) Duncan Vasey / Lucy Williams Tel: 020 7220 9797 Walbrook PR Ltd Anna Dunphy Mob: 07876 741 001 About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END PRLBRGDDSSBDGUR